Pocapavir is primarily used in the research and development of antiviral treatments, particularly for combating enterovirus infections. It has shown potential in inhibiting viral replication by targeting the viral capsid, making it a candidate for addressing severe cases of enterovirus-related diseases, such as acute flaccid myelitis and hand, foot, and mouth disease. Studies have explored its efficacy in reducing viral load and improving clinical outcomes, especially in immunocompromised patients. However, its use is still largely experimental, with ongoing clinical trials to determine its safety, effectiveness, and potential resistance issues. Pocapavir represents a promising avenue for developing targeted antiviral therapies in the future. As a research reagent, it is supplied in high purity (≥98%) for laboratory use.